Scitech Medical, has announced that it has received CE mark approval for the Embosoft microspheres for use in vascular embolization of hypervascular tumours, symptomatic uterine fibroids and prostatic arteries to relieve symptoms related to benign prostatic hyperplasia, as well as for haemostatic embolization.
According to the company, Embosoft’s high rate of viscoelasticity and its hydrophilic surface allow a selective distal embolization that is safe and effective.
Embosoft microspheres are composed of the company’s Polifit 70 material, which guarantees a well-defined spherical shape and a superior compressibility rate. Because of these characteristics, it is possible to reduce approximately 40% of its size during its delivery and will return to the initial spherical shape without fragmentation or deformation in the target vessel, the company stated.
